Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at...

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Hormonal therapy and chemotherapy are not curative for metastatic prostate cancer.
• Targeted therapy shows promise for controlling castration- and chemotherapy-resistant cells.
• A clear clinical benefit from biologic approaches in prostate cancer remains elusive.

Purpose of the Study:

• To review and outline optimized biologic therapy approaches for prostate cancer.
• To describe strategies for developing targeted therapies with clear clinical benefits.
• To highlight innovative research at Memorial Sloan-Kettering Cancer Center.

Main Methods:

• Designing targeted therapy trials based on a clinical states model incorporating patient risk and tumor biology.
• Developing multi-pathway drugs and selecting targets expressed across all disease phases.
• Utilizing new molecular imaging for target assessment and high-throughput preclinical gene expression assays for drug sequencing.

Main Results:

• Approaches are being studied to optimize biologic therapy for prostate cancer.
• Integration of clinical and biological data guides trial design.
• Advanced imaging and gene expression profiling enhance treatment selection.

Conclusions:

• Optimized biologic therapies, guided by integrated data, hold potential for advanced prostate cancer.
• Targeted approaches aim to overcome resistance to conventional treatments.
• Continued research in molecular profiling and imaging is crucial for clinical advancement.